Chamath Palihapitiya's SPAC Nearly Doubles Following Business Combo With Video Game Therapeutics Company

Zinger Key Points
  • Chamath Palihapitiya has been stuggling following lackluster trading in SPACs floated by the venture capitalists.
  • Friday, one of his SPACs skyrocketed, thanks to its business combination of a novel healthcare company.

Special purpose acquisition company Social Capital Suvretta Holdings Corp. I DNAA, sponsored by U.S.-Canadian venture capitalist Chamath Palihapitiya, jumped nearly 200% in after-hours trading on Friday.

What Happened: DNAA’s after-hours surge came on top of the nearly 50% gain the stock clocked during regular trading.

The gains look even more palatable when weighed against Friday’s broader market plunge.

In an after-hours release, digital medicine company Akili said it has completed its previously announced business combination with Palihapitiya’s Social Capital Suvretta Holdings Corp. I. The combined company, to be known as Akili, will begin trading on the Nasdaq on Aug. 22.

Akili is a healthcare company engaged in the development of cognitive treatments, leveraging technologies designed to directly target the brain.

Akili raised more than $183 million in gross proceeds from the transaction. It expects to use the proceeds to fund the commercial launch of EndeavorRx, a Food and Drug Administration-cleared and CE mark certified prescription video game for pediatric attention deficit hyperactivity disorder patients. The company expects to commercialize it in the fourth quarter.

The company also has late-stage product candidates for treating neuropsychiatric diseases, including autism spectrum disorder, multiple sclerosis, and major depressive disorder.

See also: S&P 500 Snaps 4-Week Winning Streak As Investors Anticipate Higher Interest Rates

Why It’s Important: Taking to Twitter, Palihapitiya said he is investing $100 million in Akili to “address the growing and worsening mental health crisis” in the U.S.

Palihapitiya, popularly known as the SPAC king, has seen his net worth shrink after the SPAC phenomenon lost its appeal. SPACs make up the bulk of his portfolio. Many of his portfolio companies that went public this year are trading at sub-$10 levels.

DNAA has also been trading around the level since it was listed in mid-2021.

DNAA closed Friday’s session 48.26% higher at $14.07 and added an additional 198.51% to $42 in the after-hours session, according to Benzinga Pro data.

Photo: Courtesy of TechCrunch on flickr

Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareSmall CapTrading IdeasGeneralChamath Palihapitiya
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!